Prokidney
ProKidney is a late clinical-stage biotechnology company developing rilparencel, a first-in-class autologous cell therapy that preserves kidney function in advanced CKD patients with type 2 diabetes, currently in Phase 3 trials with pivotal results expected in Q2 2027.
- Company typePublic
- Founded2015
- HeadquartersSalem, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Prokidney does
ProKidney Corp. (NASDAQ: PROK) is a late clinical-stage biotechnology company founded in 2015 and headquartered in Winston-Salem, North Carolina. It is developing rilparencel (also known as REACT), a first-of-its-kind, proprietary autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes who are at high risk of kidney failure. The therapy is administered via a novel bilateral kidney injection procedure and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Phase 2 REGEN-007 results demonstrated a statistically significant 78% improvement in annual eGFR slope decline (p<0.001) with no rilparencel-related serious adverse events, and the FDA has agreed to use eGFR slope as the primary endpoint for accelerated approval in the ongoing Phase 3 PROACT 1 study, with pivotal topline data anticipated in Q2 2027.
The company became publicly traded in July 2022 through a business combination with Social Capital Suvretta Holdings Corp. III (SPAC), and completed domestic redomiciliation to Delaware in July 2025. ProKidney operates a single-asset pipeline and is currently pre-commercial — Q2 2026 revenue was $150,000 and FY 2025 revenue was $893,000, with no approved product and no disclosed pricing model. The addressable population is approximately 1 million+ Stage 3b/4 CKD patients in the U.S., with over 135,000 progressing to dialysis annually; the broader CKD market across the seven major markets was approximately $4.8 billion in 2024. Cash and equivalents stood at $181.6 million as of Q2 2026, with management's stated runway into mid-2027, and the company has recently built out a commercial leadership team (Chief Commercial Officer in March 2026, Chief Technical Officer in June 2026) to prepare for a prospective U.S. direct launch.
Prokidney firmographics
Firmographics- Name
- Prokidney
- Legal name
- ProKidney Corp.
- Website
- https://prokidney.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- ProKidney is a late clinical-stage biotechnology company developing rilparencel, a first-in-class autologous cell therapy that preserves kidney function in advanced CKD patients with type 2 diabetes, currently in Phase 3 trials with pivotal results expected in Q2 2027.
- Ownership category
- akta.pro rank
Prokidney industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where Prokidney is headquartered
LocationHeadquarters
- HQ city
- Salem
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Prokidney business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pre-commercial / Clinical Stage Revenue: ProKidney is a late clinical-stage company without an approved commercial product. Current revenue is minimal, derived from limited sources while the company advances rilparencel through Phase 3 clinical trials toward potential commercialization. Revenue for Q2 2026 was $150,000.
Distribution channels1 record
Marketing channels3 records
Prokidney product offering
Product offeringCore offering
ProKidney is developing rilparencel (REACT®), a first-of-its-kind proprietary autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes who are at high risk of kidney failure. The therapy is administered via bilateral kidney injection using the patient's own cells and is being evaluated in the Phase 3 PROACT 1 trial. The product has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, with pivotal topline results anticipated in Q2 2027.
Product overview
ProKidney is a late clinical-stage biotechnology company with a single core product focus: rilparencel (also known as REACT®), a first-in-class autologous cell therapy. The company is evaluating rilparencel in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes at high risk of kidney failure. The product pipeline consists of this one lead candidate, which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
Differentiator
Problem solved
Functional benefit
Brands
- REACT: Renal Autologous Cell Therapy - the proprietary autologous cell therapy technology platform for rilparencel
- Rilparencel
Products and services
- Rilparencel (also known as REACT®) Rilparencel (REACT®) is ProKidney's lead product candidate — a first-of-its-kind, proprietary autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes who are at high risk of kidney failure. The therapy is administered via bilateral kidney injection using the patient's own cells and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. It is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study, with pivotal topline results anticipated in Q2 2027.
Quantifiable outcome
- 78% improvement in annual eGFR slope decline in Phase 2 REGEN-007 Group 1 patients (n=24) with advanced CKD and diabetes (p<0.001)
- +2 more outcomes
Companies that use Prokidney
Customer profileSegments1 record
Ideal customer profiles1 record
Prokidney technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Prokidney partnerships and signals
Strategic signalScale indicators10 records
Recent moves9 records
Expansion highlights4 records
Prokidney competitors and assessment
Company assessmentDirect peers
- Vertex Pharmaceuticals: Vertex is the leading commercial-stage cell and gene therapy biotech (CASGEVY), making it the most relevant direct comparator for a cell-therapy platform biotech approaching its first commercial launch.
- Vericel Corporation: Vericel markets autologous cell therapies (MACI, Epicel) and operates a personalized cell-therapy commercial model directly comparable to ProKidney's planned autologous kidney therapy launch.
- bluebird bio: bluebird bio develops and commercializes autologous gene and cell therapies, sharing manufacturing complexity, regulatory pathway, and commercial-launch dynamics with ProKidney's rilparencel.
Broad incumbents
- AstraZeneca: AstraZeneca markets Farxiga (dapagliflozin), an SGLT2 inhibitor with a major CKD label, and is the broad incumbent defining standard-of-care treatments that ProKidney would compete with or complement.
- Bayer: Bayer markets Kerendia (finerenone), the first non-steroidal MRA approved to slow CKD progression in T2D, the most direct approved small-molecule competitor to rilparencel.
- Eli Lilly / Boehringer Ingelheim: The Lilly/BI partnership markets Jardiance (empagliflozin), also indicated to slow CKD progression, and represents the large-pharma incumbent whose primary-care channel reach sets the bar for any new CKD therapy.
Emerging players
- Akebia Therapeutics: Akebia is a nephrology-focused specialty biotech with CKD and anemia-of-CKD assets, making it a comparable smaller commercial/specialty pharma competitor in the same physician channel.
- Ardelyx: Ardelyx commercializes kidney-disease therapies (Xphozah, tenapanor) and shares a nephrology specialty commercial focus with ProKidney's planned CKD launch.
- Mesoblast: Mesoblast develops allogeneic cellular medicines for inflammatory and cardiovascular conditions, providing a relevant cell-therapy comparator for manufacturing scale-up, regulatory path, and pricing.
- Chinook Therapeutics (acquired by Novartis): Chinook was a CKD-focused biotech acquired by Novartis in 2023; it serves as the bellwether for strategic value of late-stage CKD assets and validates large-pharma appetite for the indication.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Prokidney social profiles
Digital presenceProkidney compliance and trust
Trust signalCompliance1 record
Prokidney financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prokidney leadership team
Management profileNumber of profiles
Profiles7 records
Prokidney subsidiaries and ownership
Company hierarchySubsidiaries2 records
Prokidney funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prokidney M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prokidney
What does Prokidney do?
ProKidney is developing rilparencel (REACT®), a first-of-its-kind proprietary autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes who are at high risk of kidney failure. The therapy is administered via bilateral kidney injection using the patient's own cells and is being evaluated in the Phase 3 PROACT 1 trial. The product has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, with pivotal topline results anticipated in Q2 2027.
Is Prokidney a public or private company?
Prokidney is a public company. It is classified as public and is currently operating.
When was Prokidney founded?
Prokidney was founded in 2015. It employs 101 to 250 people.
Where is Prokidney based?
Prokidney is headquartered in Salem, United States, in the North America region.
How does Prokidney make money?
One revenue line is on record: pre-commercial / Clinical Stage Revenue.
Who are Prokidney's main competitors?
Direct peers on record are Vertex Pharmaceuticals, Vericel Corporation and bluebird bio. Broad incumbents are AstraZeneca, Bayer and Eli Lilly / Boehringer Ingelheim. Emerging players are Akebia Therapeutics, Ardelyx, Mesoblast and Chinook Therapeutics (acquired by Novartis).
Does Prokidney have an API?
No public API is recorded for Prokidney.
What industry is Prokidney in?
Prokidney's product category is Cell Therapy. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.